DK166757B1 - Flydende vandigt praeparat af en 2-amino-5-oxo-5h-(1)-benzopyran(2,3-b)-pyridin-3-karboxylsyre - Google Patents

Flydende vandigt praeparat af en 2-amino-5-oxo-5h-(1)-benzopyran(2,3-b)-pyridin-3-karboxylsyre Download PDF

Info

Publication number
DK166757B1
DK166757B1 DK379986A DK379986A DK166757B1 DK 166757 B1 DK166757 B1 DK 166757B1 DK 379986 A DK379986 A DK 379986A DK 379986 A DK379986 A DK 379986A DK 166757 B1 DK166757 B1 DK 166757B1
Authority
DK
Denmark
Prior art keywords
compound
solution
polyvinylpyrrolidone
aqueous liquid
preparation
Prior art date
Application number
DK379986A
Other languages
Danish (da)
English (en)
Other versions
DK379986D0 (da
DK379986A (da
Inventor
Hisayoshi Shimizu
Mitsuaki Oshima
Hideo Terayama
Original Assignee
Takeda Chemical Industries Ltd
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Senju Pharma Co filed Critical Takeda Chemical Industries Ltd
Publication of DK379986D0 publication Critical patent/DK379986D0/da
Publication of DK379986A publication Critical patent/DK379986A/da
Application granted granted Critical
Publication of DK166757B1 publication Critical patent/DK166757B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK379986A 1985-08-19 1986-08-08 Flydende vandigt praeparat af en 2-amino-5-oxo-5h-(1)-benzopyran(2,3-b)-pyridin-3-karboxylsyre DK166757B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18238385 1985-08-19
JP18238385 1985-08-19

Publications (3)

Publication Number Publication Date
DK379986D0 DK379986D0 (da) 1986-08-08
DK379986A DK379986A (da) 1987-02-20
DK166757B1 true DK166757B1 (da) 1993-07-12

Family

ID=16117350

Family Applications (1)

Application Number Title Priority Date Filing Date
DK379986A DK166757B1 (da) 1985-08-19 1986-08-08 Flydende vandigt praeparat af en 2-amino-5-oxo-5h-(1)-benzopyran(2,3-b)-pyridin-3-karboxylsyre

Country Status (10)

Country Link
US (1) US4728509A (no)
EP (1) EP0213514B1 (no)
JP (1) JPS62123116A (no)
AT (1) ATE53944T1 (no)
CA (1) CA1269618A (no)
DE (1) DE3672097D1 (no)
DK (1) DK166757B1 (no)
IE (1) IE59425B1 (no)
MY (1) MY102075A (no)
NO (1) NO171005C (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940701A (en) * 1984-01-25 1990-07-10 Beecham Group P.L.C. Topical drug release system
GB8629639D0 (en) * 1986-12-11 1987-01-21 Beecham Group Plc Composition & method
GB8629640D0 (en) * 1986-12-11 1987-01-21 Beecham Group Plc Composition & method
US4778810A (en) * 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
ES2012532A6 (es) * 1988-07-15 1990-04-01 Cusi Lab Un procedimiento para la preparacion de una solucion acuosa de b-metil-4-(2' -tienilcarbonil)fenilacetato de lisina para aplicacion topica oftalmica.
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH0714872B2 (ja) * 1990-02-06 1995-02-22 昭和薬品化工株式会社 シロップ剤組成物
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
EP0621036B1 (en) * 1993-04-22 1999-03-17 Senju Pharmaceutical Co., Ltd. Aqueous compositions comprising argatroban and cyclodextrin or caffeine
US5519030A (en) * 1993-10-07 1996-05-21 Senju Pharmaceutical Co., Ltd. Method for prophylaxis and treatment of myopia
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
KR980008226A (ko) * 1996-07-05 1998-04-30 다케다 쿠니오 시각기능장애의 예방 및 치료제
ATE253941T1 (de) * 1997-06-13 2003-11-15 Cydex Inc Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
EP1109581A1 (en) 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
JP2001125052A (ja) * 1999-10-25 2001-05-11 Lion Corp コンタクトレンズ装着液
KR100791871B1 (ko) * 2000-06-19 2008-01-07 산텐 세이야꾸 가부시키가이샤 방부제
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
KR20070104884A (ko) 2004-11-24 2007-10-29 메드포인트 헬쓰케어 인크. 아젤라스틴을 포함하는 조성물 및 이의 사용 방법
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
JP5642929B2 (ja) 2005-03-10 2014-12-17 スリーエム イノベイティブ プロパティズ カンパニー 微小生体汚染の低減方法
US20070010465A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009531A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
ES2752008T3 (es) * 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
KR20130094293A (ko) * 2010-07-21 2013-08-23 알콘 리서치, 리미티드 향상된 용해도 특성들을 갖는 약학 조성물
WO2012112558A1 (en) 2011-02-14 2012-08-23 The Regents Of The University Of Michigan Compositions and methods for the treatment of obesity and related disorders
CN107261152B (zh) 2011-11-29 2022-03-04 优奥斯私人有限公司 包含环糊精和疏水性药物的可注射药物组合物的防腐方法
EP2991647B1 (en) 2013-05-02 2019-04-24 The Regents Of The University Of Michigan Deuterated amlexanox with improved metabolic stability
US10214536B2 (en) 2016-01-29 2019-02-26 The Regents Of The University Of Michigan Amlexanox analogs
EP3505154B1 (en) * 2017-12-26 2022-04-06 Industrial Technology Research Institute Composition for improving the solubility of poorly soluble substances, use thereof and complex formulation containing thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD7498A1 (de) * 1951-02-20 1954-05-31 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung von haltbaren Lösungen in 1,3-Stellung substituierter Xanthine
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
JPS53111096A (en) * 1977-03-08 1978-09-28 Takeda Chem Ind Ltd 1-azaxanthone-3-carboxylic acid derivative and its preparation
AU513456B2 (en) * 1977-03-08 1980-12-04 Takeda Chemical Industries Ltd. l-Azaxanthone-3-carboxylic acids
JPS54115398A (en) * 1978-02-27 1979-09-07 Takeda Chem Ind Ltd 1-azaxanthone-3-carboxylic acid derivative and its preparation
JPS6042766B2 (ja) * 1978-12-09 1985-09-25 日本化薬株式会社 基剤
ZA815175B (en) * 1980-08-01 1982-09-29 Smith & Nephew Ass Pharmaceutical composition
JPS57200361A (en) * 1981-06-03 1982-12-08 Sumitomo Chem Co Ltd "indomethacin(r)" pharmaceutical with low irritant action
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
JPS58174310A (ja) * 1982-04-06 1983-10-13 Wakamoto Pharmaceut Co Ltd 抗炎症点眼剤
DE3372705D1 (en) * 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
US4539326A (en) * 1982-08-20 1985-09-03 Takeda Chemical Industries, Ltd. 5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use as anti-inflammatory agents
US4559343A (en) * 1982-09-07 1985-12-17 Alcon Laboratories, Inc. Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents
JPS59106424A (ja) * 1982-12-09 1984-06-20 Kyorin Pharmaceut Co Ltd 易吸収性キノリンカルボン酸誘導体組成物およびその製剤
JPS59152320A (ja) * 1983-02-17 1984-08-31 Takeda Chem Ind Ltd 水性製剤
KR920010047B1 (ko) * 1985-01-28 1992-11-13 다께다야꾸힝고오교 가부시끼가이샤 2-아미노-5-옥소-5H-[1]벤조피라노[2,3-b]피리딘-3-카르복실산 유도체의 제조방법

Also Published As

Publication number Publication date
NO171005B (no) 1992-10-05
DK379986D0 (da) 1986-08-08
EP0213514B1 (en) 1990-06-20
JPH0478614B2 (no) 1992-12-11
CA1269618A (en) 1990-05-29
US4728509A (en) 1988-03-01
EP0213514A3 (en) 1987-07-22
EP0213514A2 (en) 1987-03-11
DE3672097D1 (de) 1990-07-26
JPS62123116A (ja) 1987-06-04
MY102075A (en) 1992-03-31
DK379986A (da) 1987-02-20
NO863253D0 (no) 1986-08-12
NO863253L (no) 1987-02-20
NO171005C (no) 1993-01-13
ATE53944T1 (de) 1990-07-15
IE59425B1 (en) 1994-02-23
IE862214L (en) 1987-02-19

Similar Documents

Publication Publication Date Title
DK166757B1 (da) Flydende vandigt praeparat af en 2-amino-5-oxo-5h-(1)-benzopyran(2,3-b)-pyridin-3-karboxylsyre
KR920001461B1 (ko) 안과 액제의 제조방법
JPH07116029B2 (ja) トラニラスト水溶液製剤
BG65304B1 (bg) Воден състав, съдържащ моксифлоксацин и натриев хлорид
TWI544934B (zh) 含有氟喹諾酮抗生素藥物之經改良藥學組成物
JPH1160505A (ja) 防腐組成物
WO2005101982A2 (en) A stable ophthalmic composition
AU2014212274A1 (en) Aqueous ophthalmic solutions of phentolamine and medical uses thereof
JP3659801B2 (ja) トラニラスト水溶液製剤
EP0233615B1 (en) Aqueous preparation and method of preparation thereof
JP2916340B2 (ja) ナトリウムクロモグリケートの水性医薬組成物
KR20080053319A (ko) 브리부딘을 함유하는 헤르페스 각막염 치료용 광안정 약학조성물
EP0348527B1 (en) Antiallergic eye drop
JPH03109326A (ja) フレロキサシン点眼液
JP2003192583A (ja) 消炎点眼剤
JP2004238346A (ja) トラニラストの安定な水溶液製剤
BR112021001339A2 (pt) composições e métodos para tratar os olhos
JPH1029937A (ja) メフェナム酸水溶液製剤
CA2718826A1 (en) Gatifloxacin-containing aqueous liquid preparation
JP2822049B2 (ja) 水性製剤組成物
KR102444571B1 (ko) 세티리진 및 토코페솔란을 포함하는 안과용 조성물
JPH08268892A (ja) 水溶液製剤及びその製造方法
WO2013055073A2 (ko) 사이클로스포린 함유 안약 조성물 및 그 제조방법
US20110082128A1 (en) In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
JP2001131064A (ja) トラニラスト膏体組成物及びその製造方法

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed